News and Events
Upcoming Events
September 14, 2026
September 24 ICOC/ARS Meeting
August 28, 2026
Public Comment for Rocket Pharmaceuticals Kresladi Access Plan
August 28, 2026
September 8 Governance Subcommittee Meeting
August 24, 2026
September 3 Communications Subcommittee Meeting
Latest Press Releases
September 25, 2026
CIRM approves more than $195 million to support education, discovery, clinical, and infrastructure awards
September 25, 2026
El CIRM destina $9 millones a Enloe Health para acercar las terapias celulares y génicas a los pacientes del norte de California
September 25, 2026
CIRM awards $9 million to Enloe Health to bring cell and gene therapies closer to patients in Northern California
June 25, 2026
CIRM advances $662 million research budget, the largest annual investment in its history
CIRM’s Blog: The Stem Cellar
The Stem Cellar
- Tr1X Bio aims to Redefine Cell Therapy for Autoimmune Diseases October 21, 2026Maria Grazia Roncarolo believes her company could redefine treatments for conditions like multiple sclerosis (MS), Crohn’s disease, and other autoimmune diseases. Closer to Cures Dr. Roncarolo, co-founder, president, and head of R&D at San Diego-based Tr1X Bio, said in a recent presentation that her company is modifying the patient’s own immune system to calm cells […]
- Connecting with and engaging Californians for public health October 14, 2026By Holly Alyssa MacCormick If you or someone you love is living with a chronic disease, you know that navigating uncertainty and getting answers can be one of the hardest parts of the journey. That’s why Aditi Desai’s work matters. As the community outreach manager for the California Institute for Regenerative Medicine (CIRM), Desai focuses on […]
- Another proof point from CIRM-supported research October 7, 2026When Alameda-based biotech company and CIRM awardee Scribe Therapeutics raised over $155 million from a recent IPO, it became the latest in a series of companies developing CIRM-supported therapies that have gone public or netted significant follow-on funding and investment. That’s good news for Californians whose tax dollars support the companies’ work. While biotech IPOs […]